A1CF | APOBEC1 complementation factor | | | | | | Tissue enhanced |
ABCC6 | ATP-binding cassette, sub-family C (CFTR/MRP), member 6 | Cancer-related genes Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ABCD2 | ATP-binding cassette, sub-family D (ALD), member 2 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
ADAMTS1 | ADAM metallopeptidase with thrombospondin type 1 motif, 1 | Cancer-related genes Enzymes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ADIRF | Adipogenesis regulatory factor | Plasma proteins
| | | | | Tissue enhanced |
AFAP1L2 | Actin filament associated protein 1-like 2 | | | | | | Tissue enhanced |
AGAP2 | ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 | | | | | | Tissue enhanced |
AIM1L | Absent in melanoma 1-like | | | | | | Tissue enhanced |
AK4 | Adenylate kinase 4 | Enzymes Mitochondrial proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AKNAD1 | AKNA domain containing 1 | | | | | | Tissue enhanced |
ALDH1L2 | Aldehyde dehydrogenase 1 family, member L2 | Enzymes
| | | | | Tissue enhanced |
ALDH3A1 | Aldehyde dehydrogenase 3 family, member A1 | Enzymes
| | | | | Tissue enhanced |
ALPK2 | Alpha-kinase 2 | Cancer-related genes Enzymes
| | | | | Tissue enhanced |
ALPL | Alkaline phosphatase, liver/bone/kidney | Cancer-related genes Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ALX1 | ALX homeobox 1 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
ANLN | Anillin, actin binding protein | | | | | | Tissue enhanced |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ANO2 | Anoctamin 2 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ANXA13 | Annexin A13 | Plasma proteins
| | | | | Tissue enhanced |
AOX1 | Aldehyde oxidase 1 | Enzymes Plasma proteins
| | | | | Tissue enhanced |
APOBEC3A | Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A | | | | | | Tissue enhanced |
ARHGAP28 | Rho GTPase activating protein 28 | | | | | | Tissue enhanced |
ARHGEF33 | Rho guanine nucleotide exchange factor (GEF) 33 | | | | | | Tissue enhanced |
ARID3A | AT rich interactive domain 3A (BRIGHT-like) | Transcription factors
| | | | | Tissue enhanced |
ARNTL2 | Aryl hydrocarbon receptor nuclear translocator-like 2 | Transcription factors
| | | | | Tissue enhanced |
ASB9 | Ankyrin repeat and SOCS box containing 9 | | | | | | Tissue enhanced |
ASS1 | Argininosuccinate synthase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
AUNIP | Aurora kinase A and ninein interacting protein | | | | | | Tissue enhanced |
BAG2 | BCL2-associated athanogene 2 | Plasma proteins
| | | | | Tissue enhanced |
BARX2 | BARX homeobox 2 | Transcription factors
| | | | | Tissue enhanced |
BASP1 | Brain abundant, membrane attached signal protein 1 | Cytoskeleton related proteins Plasma proteins Transporters
| | | | | Tissue enhanced |
BCL2L14 | BCL2-like 14 (apoptosis facilitator) | | | | | | Tissue enhanced |
BNC2 | Basonuclin 2 | Transcription factors
| | | | | Tissue enhanced |
BRIP1 | BRCA1 interacting protein C-terminal helicase 1 | Cancer-related genes Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
BSPRY | B-box and SPRY domain containing | | | | | | Tissue enhanced |
BTK | Bruton agammaglobulinemia tyrosine kinase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
BUB1 | BUB1 mitotic checkpoint serine/threonine kinase | Enzymes
| | | | | Tissue enhanced |
BUB1B | BUB1 mitotic checkpoint serine/threonine kinase B | Cancer-related genes Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
C11orf63 | Chromosome 11 open reading frame 63 | | | | | | Tissue enhanced |
C15orf27 | Chromosome 15 open reading frame 27 | Predicted membrane proteins
| | | | | Tissue enhanced |
C16orf46 | Chromosome 16 open reading frame 46 | | | | | | Tissue enhanced |
C17orf53 | Chromosome 17 open reading frame 53 | | | | | | Tissue enhanced |
C18orf54 | Chromosome 18 open reading frame 54 | Predicted secreted proteins
| | | | | Tissue enhanced |
C1orf110 | Chromosome 1 open reading frame 110 | | | | | | Tissue enhanced |
C21orf58 | Chromosome 21 open reading frame 58 | | | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
CALB2 | Calbindin 2 | Plasma proteins
| | | | | Tissue enhanced |
CAMK4 | Calcium/calmodulin-dependent protein kinase IV | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |